In commercial-stage single-product biotechs, gross margin compression driven by manufacturing investment (new delivery systems, capacity build-out, COGS scale) is structurally different from competitive pricing erosion. The distinguishing signal: operating margin expanding concurrently with gross margin declining means SG&A leverage is outrunning COGS increase — the business is healthy even as the GM headline deteriorates. Default to flagging GM compression as a risk only when op margin is also compressing, or when revenue growth is slowing simultaneously.
When reviewing commercial biotech financials, separate the GM trend from the op margin trend before drawing conclusions. A GM declining 100-200bps/quarter with op margin expanding 200-400bps is a positive operating leverage story, not a margin deterioration story. Build this as an explicit check: if GM is compressing, ask "is this pricing pressure (bearish) or manufacturing investment (neutral to bullish)?" Review COGS line items for scale-up language in earnings transcripts as the diagnostic. Apply the same lens to any hardware-attached or manufacturing-intensive business where COGS scale ahead of revenue ramp.